ANI Pharmaceuticals Stock (NASDAQ:ANIP)
Previous Close
$55.25
52W Range
$48.20 - $70.81
50D Avg
$58.34
200D Avg
$62.17
Market Cap
$1.17B
Avg Vol (3M)
$314.06K
Beta
0.71
Div Yield
-
ANIP Company Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANIP Performance
Peer Comparison
Ticker | Company |
---|---|
ALKS | Alkermes plc |
IRWD | Ironwood Pharmaceuticals, Inc. |
COLL | Collegium Pharmaceutical, Inc. |
PBH | Prestige Consumer Healthcare Inc. |
AMPH | Amphastar Pharmaceuticals, Inc. |
NBIX | Neurocrine Biosciences, Inc. |
PCRX | Pacira BioSciences, Inc. |
EGRX | Eagle Pharmaceuticals, Inc. |
RDY | Dr. Reddy's Laboratories Limited |
PAHC | Phibro Animal Health Corporation |
DCPH | Deciphera Pharmaceuticals, Inc. |